Back

Plasma glycome reflects low back pain progression and is not predictive of acute-to-chronic pain transition

Elgaeva, E. E.; Trbojevic-Akmacic, I.; Ugrina, I.; Vilaj, M.; Slana, A.; Pribic, T.; Tsepilov, Y. A.; Karssen, L. C.; Aulchenko, Y. S.; Dagostino, C.; Allegri, M.; Skelin, A.; Primorac, D.; Buyse, K.; Van Zundert, J.; Lauc, G.; Williams, F. M. K.; Freidin, M. B.

2024-11-13 pain medicine
10.1101/2024.11.12.24314768 medRxiv
Show abstract

AimsTo investigate if the plasma N-glycome would provide a biomarker of acute-to-chronic low back pain (LBP) transition. Patients & MethodsA prospective longitudinal sample of n = 1,114 individuals enrolled at the first ever episode of LBP and followed-up for three months. Total plasma N-glycome was measured and compared at the baseline and follow-up. ResultsInitial pro-inflammatory patterns of plasma N-glycome change to normal levels between baseline and follow-up in those who resolved from LBP, but not in those who remained at pain after three months. Baseline levels of N-glycans were not predictive of the risk of chronic LBP at follow-up. ConclusionTotal plasma N-glycan levels may reflect ongoing inflammation that is aberrant and promotes ongoing pain and chronicity of symptoms.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.